GLP1R and cardiovascular disorder: This is a meta-analysis of trial data, which is inferior to patient-level meta-analysis. The study used aggregate data, so patient subgroups (with and without cardiovascular disease) could not be investigated. Differences in gender were not considered, and the possible superiority of a drug within the GLP1-RA class was also not investigated.